ClinicalTrials.gg
RecruitingNCT05999994CAMPFIREUpdated Aug 7, 2026

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

A Phase 2 interventional study of Ramucirumab and Cyclophosphamide in Neoplasms, Child and Adolescent, sponsored by Eli Lilly and Company. Recruiting at 72 sites in 10 countries. Open to participants aged 1 Year to 39 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Jan 2020, registered Aug 2023).
  • Started Jan 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
1 Year to 39 Years
Sex
All
01

Study summary

The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.

02

Conditions studied

  • Neoplasms
  • Child
  • Adolescent

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 105 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 39 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Participants must meet all of the inclusion criteria below. Additional criteria are specified in the protocol amendment (individual addenda) to which the participant will enroll.

  • Have either measurable or evaluable disease using standard techniques by the , Version 1.1 (RECIST 1.1).
  • The participant has a Lansky (\<16 years of age) or (≥16 years of age) performance score of at least 50.
  • Participants must have discontinued all previous treatments for cancer or agents greater than or equal to (≥)7 days after the last dose and must have recovered from side effects.
  • The participant has adequate hematologic and organ function.
  • Female participants of must have a negative urine or serum pregnancy test within 7 days prior to first dose.
  • Both female and male participants of childbearing potential must agree to use highly effective precautions during the trial and for at least 3 months following the last dose of study drug.

Participants will be ineligible if they meet any of the exclusion criteria below. Additional criteria are specified in the protocol amendment to which the participant will enroll.

  • Participants with severe and/or uncontrolled concurrent medical disease or psychiatric illness/social situation that, in the opinion of the investigator, could cause unacceptable safety risks or compromise compliance with the protocol.
  • Participants who have active infections requiring therapy.
  • Participants who have had allogeneic bone marrow or solid organ transplant.
  • Participants who have had, or are planning to have, certain invasive procedures.
  • Female participants who are pregnant or breastfeeding.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Ramucirumab + Cyclophosphamide + Vinorelbine (DSRCT ISA)

    Ramucirumab given intravenously (IV), cyclophosphamide given orally and vinorelbine given IV in 28-day cycles for desmoplastic small round cell tumor (DSRCT) intervention-specific appendix (ISA).

    Drug: Ramucirumab · Drug: Cyclophosphamide · Drug: Vinorelbine

  • Active comparator
    Cyclophosphamide + Vinorelbine (DSRCT ISA)

    Cyclophosphamide given orally and vinorelbine given IV in 28-day cycles for DSRCT ISA.

    Drug: Cyclophosphamide · Drug: Vinorelbine

  • Experimental
    Ramucirumab + Gemcitabine + Docetaxel (SS ISA)

    Ramucirumab and gemcitabine given IV in 21-day cycles for synovial sarcoma (SS) ISA.

    Drug: Ramucirumab · Drug: Gemcitabine · Drug: Docetaxel

  • Active comparator
    Gemcitabine + Docetaxel (SS ISA)

    Gemcitabine and docetaxel given IV in 21-day cycles for SS ISA.

    Drug: Gemcitabine · Drug: Docetaxel

  • Experimental
    Abemaciclib + Irinotecan + Temozolomide (ES ISA)

    Abemaciclib given orally, irinotecan given IV, and temozolomide given orally in 21-day cycles for Ewing's sarcoma (ES) ISA.

    Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide

  • Active comparator
    Irinotecan + Temozolomide (ES ISA)

    Irinotecan given IV and temozolomide given orally in 21-day cycles for ES ISA.

    Drug: Irinotecan · Drug: Temozolomide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Allocated to Each ISA

    Number of Participants Allocated to Each ISA

    Time frame: Baseline up to Week 4

07

Study locations

52 of 72 sites recruiting
  • Childrens Hospital of Alabama
    Birmingham, Alabama 35233, United States
    Not yet recruiting
    • Gregory Friedman · Principal investigator
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
    Recruiting
    • · Contact602-546-0990
    • Alok Kothari · Principal investigator
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
    Recruiting
    • Alok Kothari · Principal investigator
  • Childrens Hospital of Los Angeles
    Los Angeles, California 90027, United States
    Completed

    Not enrolling at this site — choose another above.

  • UCLA Medical Center
    Los Angeles, California 90095, United States
    Not yet recruiting
    • Noah Federman · Principal investigator
  • Children's Hospital of Orange County
    Orange, California 92868, United States
    Recruiting
    • Josephine HaDuong · Principal investigator
  • Children's Hospital of Colorado
    Denver, Colorado 80218, United States
    Recruiting
    • · Contact720-777-6740
    • Margaret Macy · Principal investigator
  • Children's National Medical Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • · Contact202-476-4744
    • AeRang Kim · Principal investigator
  • Golisano Children's Hospital of Southwest Florida
    Fort Myers, Florida 33908, United States
    Recruiting
    • · Contact239-343-5437
    • Emad Salman · Principal investigator
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224, United States
    Recruiting
    • · Contact904-953-2000
    • Steven Attia · Principal investigator
  • Children's Healthcare of Atlanta, Inc. at Egleston
    Atlanta, Georgia 30322, United States
    Not yet recruiting
    • · Contact404-785-0910
    • Thomas Cash · Principal investigator
  • Ann & Robert H Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
    Recruiting
    • · Contact312-227-4834
    • David Walterhouse · Principal investigator
  • Riley Hospital for Children
    Indianapolis, Indiana 46202-5225, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Not yet recruiting
    • · Contact617-632-5869
    • Natalie Collins · Principal investigator
  • C.S. Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
    Not yet recruiting
    • · Contact734-615-7790
    • Rajen Mody · Principal investigator
  • University of Minnesota Hospital
    Minneapolis, Minnesota 55455, United States
    Not yet recruiting
    • · Contact612-626-3593
    • Emily Greengard · Principal investigator
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • · Contact816-302-6808
    • Kevin Ginn · Principal investigator
  • Washington University Medical School
    St Louis, Missouri 63110, United States
    Completed

    Not enrolling at this site — choose another above.

  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • · Contact212-639-8856
    • Emily Slotkin · Principal investigator
  • Nationwide Children's Hosp
    Columbus, Ohio 43205-2664, United States
    Recruiting
    • · Contact614-355-1202
    • Mark Ranalli · Principal investigator
  • Oregon Health and Science University
    Portland, Oregon 97201, United States
    Not yet recruiting
    • · Contact503-494-4671
    • Katrina Winsnes · Principal investigator
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Completed

    Not enrolling at this site — choose another above.

  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
    • Andrew Bukowinski · Principal investigator
  • Lifespan Cancer Institute
    Providence, Rhode Island 02906, United States
    Recruiting
    • · Contact401-829-6552
    • Bradley DeNardo · Principal investigator
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 75390-9063, United States
    Recruiting
    • Theodore Laetsch · Principal investigator
  • Cook Children's Hospital
    Fort Worth, Texas 76104-2724, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Texas Childrens Hospital
    Houston, Texas 77025, United States
    Not yet recruiting
    • · Contact832-824-4632
    • Jodi Muscal · Principal investigator
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
    • · Contact713-745-6754
    • Najat Daw · Principal investigator
  • Seattle Children's Hospital Research Foundation
    Seattle, Washington 98105, United States
    Recruiting
    • · Contact206-987-2114
    • Catherine Albert · Principal investigator
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
    • · Contact414-456-4170
    • Meghen Browning · Principal investigator
  • Chris O'Brien Lifehouse
    Camperdown, 2050, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Peter MacCallum Cancer Centre
    Melbourne, 3000, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Royal Children's Hospital
    Melbourne, 3052, Australia
    Completed

    Not enrolling at this site — choose another above.

  • UCL- Saint Luc
    Brussels, 1200, Belgium
    Recruiting
    • · Contact3227642376
    • Benedicte Brichard · Principal investigator
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
    Completed

    Not enrolling at this site — choose another above.

  • Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
    Bordeaux, 33076, France
    Recruiting
    • Antoine Italiano · Principal investigator
  • Centre Leon Berard
    Lyon, 69008, France
    Not yet recruiting
    • · Contact33478785126
    • Jean Yves Blay · Principal investigator
  • Centre Leon Berard
    Lyon, 69008, France
    Recruiting
    • · Contact+33478782642
    • Nadege Corradini · Principal investigator
  • Institut Curie
    Paris, 75248, France
    Not yet recruiting
    • · Contact33144324068
    • Sophie Piperno-Neumann · Principal investigator
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
    Recruiting
    • · Contact492017232255
    • Uta Dirksen · Principal investigator
  • Universitaetsklinikum Freiburg
    Freiburg im Breisgau, 79106, Germany
    Recruiting
    • Simone Hettmer · Principal investigator
  • Universitaetsklinikum Hamburg-Eppendorf
    Hamburg, 20251, Germany
    Recruiting
    • · Contact4940741020622
    • Uwe Kordes · Principal investigator
  • IRCCS Istituto Ortopedico Rizzoli
    Bologna, 40136, Italy
    Recruiting
    • · Contact390516366411
    • EMANUELA PALMERINI · Principal investigator
  • Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia
    Candiolo, 10060, Italy
    Recruiting
    • · Contact390119933278
    • Massimo Aglietta · Principal investigator
  • Istituto Nazionale dei Tumori
    Milan, 20133, Italy
    Recruiting
    • · Contact39022393062
    • Andrea Ferrari · Principal investigator
  • Azienda Ospedaliera Di Padova
    Padova, 35128, Italy
    Recruiting
    • Gianni Bisogno · Principal investigator
  • Ospedale Bambino Gesu
    Roma, 00165, Italy
    Recruiting
    • · Contact390668592444
    • Giuseppe Milano · Principal investigator
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    Roma, 00168, Italy
    Recruiting
    • Antonio Ruggiero · Principal investigator
  • Istituto Clinico Humanitas
    Rozzano, 20089, Italy
    Recruiting
    • Alexia Bertuzzi · Principal investigator
  • National Cancer Center Hospital
    Chūōku, 104-0045, Japan
    Recruiting
    • · Contact81120023812
    • Chitose Ogawa · Principal investigator
  • Kyushu University Hospital
    Fukuoka, 812-8582, Japan
    Recruiting
    • · Contact81120023812
    • Yuhki Koga · Principal investigator
  • Hyogo Prefectural Kobe Children's Hospital
    Kobe, 650-0047, Japan
    Recruiting
    • · Contact81120023812
    • Daiichiro Hasegawa · Principal investigator
  • Leids Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
    Recruiting
    • Hans Gelderblom · Principal investigator
  • Prinses Maxima Centrum
    Utrecht, 3584 CS, Netherlands
    Recruiting
    • · Contact31650006353
    • Natasha van Eijkelenburg · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
    Recruiting
    • Antonio Lopez Pousa · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
    Recruiting
    • Claudia Maria Valverde Morales · Principal investigator
  • Hospital Universitari Vall d'Hebron
    Barcelona, 8035, Spain
    Recruiting
    • Lucas Moreno Martin Retortillo · Principal investigator
  • Hospital Sant Joan de Déu
    Esplugues de Llobregat, 8950, Spain
    Recruiting
    • · Contact34932532100
    • Jaume Mora Graupera · Principal investigator
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
    Recruiting
    • Rosa Alvarez Alvarez · Principal investigator
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
    Recruiting
    • Maria Cristina Mata Fernandez · Principal investigator
  • Hospital Infantil Universitario Niño Jesús
    Madrid, 28009, Spain
    Recruiting
    • Alba Rubio San Simón · Principal investigator
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • Andres Redondo Sanchez · Principal investigator
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • Pedro Rubio · Principal investigator
  • Hospital Universitario de Canarias
    San Cristóbal de La Laguna, 38320, Spain
    Recruiting
    • Josefina Cruz Jurado · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Recruiting
    • Maria Jose Flor Oncala · Principal investigator
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Recruiting
    • · Contact34955012593
    • Catalina Marquez-Vega · Principal investigator
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
    Recruiting
    • Antonio Juan Ribelles · Principal investigator
  • University College Hospital - London
    London, NW1 2PG, United Kingdom
    Recruiting
    • Sandra Strauss · Principal investigator
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
    Recruiting
    • Julia Chisholm · Principal investigator
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
    Recruiting
    • ROBIN JONES · Principal investigator
  • Royal Manchester Children's Hospital
    Manchester, M13 9WL, United Kingdom
    Recruiting
    • Bernadette Brennan · Principal investigator
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
    Recruiting
    • Martin McCabe · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2020 (actual). Primary completion is estimated for May 2027, 88 months after the start.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's planned 88 months is above that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Jan 22, 2020
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05999994
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Jan 22, 2020
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ramucirumab · Cyclophosphamide · Vinorelbine · Gemcitabine · Docetaxel · Abemaciclib · Irinotecan · Temozolomide

Start the discussion